Everything below concerns Mod GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Narrated by Juliet Stevenson, produced by Chris Haws, made by InCA Productions 23 December Going Downhill Fast, with the British Olympic speed skiing team, sponsored by Nevisport; Les Arcs in April 1990; British team manager, George Brown; refrigeration engineer Malcolm Clulow of Snowmec; the Holmenkollbakken and Holmenkollen Ski Museum near Oslo; Skis Rossignol; Tento, Bratlie, Østbye and Grafitt-Voks ski wax; Norwegian chemist Leif Torgersen of Swix and SINTEF; Swix Cera wax made from perfluorooctanoic acid (C8); Scottish speed skier Robbie Brown in a wind tunnel at the Norwegian University of Science and Technology, with Helge Nørstrud; Finnish skier Kalevi Häkkinen; British speed skier Henry Iddon. Narrated by Tom Cotcher, produced by Chris Haws, directed by Andy Fairgrieve, made by InCA
=== Mass-18 notation === Under some circumstances, the abundances of 13CH3D and 12CH2D2 isotopologues are only measured as a sum, which leads to the notation for isotopologues of mass-18 (i.e. 13CH3D and 12CH2D2):
Grameen Danone Foods, popularly known as Grameen Danone, is a social business enterprise, launched in 2006, which has been designed to provide children with many of the key nutrients that are typically missing from their diet in rural Bangladesh. It is run on 'No loss, No dividend' basis. Initially, Grameen Danone agreed to pay an annual dividend of one percent to shareholders, however, in December 2009, the board of Grameen Danone agreed to waive any monetary return.
=== 1970s === The scientific and medical markets have always been important for Edwards. The introduction of X-ray technology required the use of a vacuum. Vacuum technology also played an important role in the development of neuroimaging (brain scanners), like MRI, CT, and PET scanners. The first home computers were brought to the market in the 1970s and the development of computer technology has been unstoppable ever since. The mass production of CRT displays and integrated circuits necessitated electronic companies to scale up, with vacuum installations becoming bigger and demand for vacuum purity increasing. In the 1970s, Edwards Vacuum also collaborated with Seiko Seiki for the invention of magnetically suspended turbopumps. These molecular turbopumps use magnetically levitated bearings, which eliminate the risk of vacuum contamination, require less maintenance, and feature lower noise and vibration levels. This type of technology is particularly suitable for scientific applications and the harsh processes in semiconductor manufacturing. The newly emerged dry pumps and turbomolecular pumps supported innovation in the scientific instrument markets over the next couple of decades. The scientific instrument market is now the second biggest market for Edwards Vacuum, after the semiconductor and electronics industry.
While European ETSI standards have supported WMAS for several years, the U.S. Federal Communications Commission (FCC) officially adopted rules in February 2024 to allow WMAS operation in the United States. This regulatory change led to the introduction of wideband digital platforms such as Sennheiser’s Spectera and Shure’s Axient Digital PSM (ADPSM), which allow for bidirectional audio and increased spectral efficiency at large-scale events.
Sources: en.wikipedia.org
process molecular gene concept An alternative definition of a gene which emphasizes the contribution of non-DNA factors to the process by which the information encoded in a DNA sequence results in the synthesis of a polypeptide.
{\displaystyle {\frac {\omega }{k}}=\left[{\frac {1}{2}}\left(v_{\text{A}}^{2}+v_{\text{s}}^{2}\pm {\sqrt {\left(v_{\text{A}}^{2}+v_{\text{s}}^{2}\right)^{2}-4v_{\text{s}}^{2}v_{\text{A}}^{2}\cos ^{2}\theta }}\right)\right]^{1/2}}
=== 25 June === The International Criminal Court issued arrest warrants against former Russian defence minister Sergei Shoigu and Chief of the General Staff Valery Gerasimov for war crimes and crimes against humanity pertaining to strikes on Ukrainian energy facilities from 2022 to 2023. The HUR claimed to have blown up a Russian ammunition depot in Voronezh Oblast. The governor of Belgorod Oblast claimed that one person was killed in a drone strike. Czech Prime Minister Petr Fiala said that the first batch of artillery ammunition purchased under the Czech-led initiative had been delivered to Ukraine. Russia and Ukraine conducted a prisoner exchange involving 90 POWs from each side. One of the prisoners swapped was a Ukrainian Orthodox priest who had been convicted and sentenced for “justifying Russian armed aggression“.
Alternatively some may use titles specific to the discipline they train in, such as "trainee clinical biochemist", "clinical immunologist in training" or "pre-registrant clinical microbiologist", which is also acceptable since it is not implying the protected "clinical scientist" title of fully qualified and registered practitioners. It is against the law to formally work with the title of "clinical scientist" without professional registration.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.